The ASB9 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited A-549 cell population carrying targeted disruption of the ASB9 gene. This polyclonal knockout pool is generated by delivering Cas9 and guide RNAs against ASB9, resulting in a heterogeneous mixture of indels. It provides a loss-of-function model to study ASB9 biology without clonal selection artifacts.
The parental A-549 cell line is a human lung adenocarcinoma epithelial model derived from a 58-year-old Caucasian male. These adherent cells are widely used in respiratory disease and cancer research, retaining alveolar type II characteristics such as surfactant production and cytokine responsiveness. Their robust growth and well-characterized signaling make them suitable for genetic engineering and functional assays.
ASB9 encodes a substrate recognition subunit of the Elongin B/C-Cullin-5-Rbx2 (ECS) E3 ubiquitin ligase complex. It interacts with Elongin B, Elongin C, Cullin-5, and Rbx2 to ubiquitinate target proteins for 26S proteasomal degradation. This process is regulated by cytokines such as IL-6 and IFN-?? via JAK-STAT pathway activation. Although substrates remain largely unidentified, its SOCS box domain implicates ASB9 in controlling STAT protein turnover, thereby modulating cytokine signaling outputs.
In A-549 lung adenocarcinoma cells, ASB9 knockout enables dissection of how ECS-mediated ubiquitination intersects with cytokine-driven oncogenic signaling. A-549 cells respond robustly to IL-6 and IFN-??, making them ideal for investigating the impact of ASB9 loss on JAK-STAT dynamics, proliferation, apoptosis, and migration. Given the role of ubiquitin-proteasome dysregulation in cancer, this model may uncover mechanisms of tumor maintenance or drug resistance.
This knockout model supports applications such as proliferation and migration assays (MTT, Transwell), apoptosis analysis (Annexin V), and phospho-STAT flow cytometry. Ubiquitination assays can probe ASB9 substrate stability. The polyclonal population reduces clone-specific artifacts in drug sensitivity studies. Contact Ascent Research for lot-specific details and technical assistance.
